We serve Chemical Name:methyl 3-bromo-5-chloropyridine-2-carboxylate CAS:1214362-45-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:methyl 3-bromo-5-chloropyridine-2-carboxylate
CAS.NO:1214362-45-4
Synonyms:Methyl 3-bromo-5-chloropicolinate;3-Bromo-5-chloro-2-(methoxycarbonyl)pyridine
Molecular Formula:C7H5BrClNO2
Molecular Weight:250.47700
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:39.19000
Exact Mass:248.91900
LogP:2.28410
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Methyl 3-bromo-5-chloropicolinate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Bromo-5-chloro-2-(methoxycarbonyl)pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Bromo-5-chloro-2-(methoxycarbonyl)pyridine Use and application,Methyl 3-bromo-5-chloropicolinate technical grade,usp/ep/jp grade.
Related News: Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. methyl 3-bromo-5-chloropyridine-2-carboxylate manufacturer It has reserves in the direction of APIs and intermediates for lowering blood lipids, lowering blood sugar and anticoagulation. methyl 3-bromo-5-chloropyridine-2-carboxylate supplier China has granted conditional approval to its first self-developed treatment for Alzheimer��s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug. methyl 3-bromo-5-chloropyridine-2-carboxylate vendor Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. methyl 3-bromo-5-chloropyridine-2-carboxylate factory China has granted conditional approval to its first self-developed treatment for Alzheimer��s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.
